One of the major challenges faced by the global fusion biopsy market is the high cost of fusion biopsy systems. These advanced biopsy systems that integrate MRI/TRUS imaging with biopsy require expensive MRI or ultrasound devices along with the biopsy hardware and software. This pushes the total installation cost of a fusion biopsy system to over half a million dollars or more. The steep capital investment poses a significant barrier for small hospitals and clinics in developing countries to adopt fusion biopsy. Moreover, the need for regular maintenance and software upgrades further adds to the operational costs. The pricing pressure to recover the high fixed costs also makes fusion biopsy procedures relatively expensive for patients compared to conventional biopsy.
Market Opportunity - Growing demand for minimally invasive diagnostic procedures
A key opportunity for the global fusion biopsy market is the rising demand for minimally invasive diagnostic procedures across the world. There is an increasing preference for procedures that are less painful, cause minimal trauma to tissues and enable faster recovery. Compared to conventional transrectal ultrasound (TRUS) biopsies which require multiple needles insertions, fusion biopsy provides precise tissue sampling with just one insertion guided by multi-parametric MRI images. This significantly reduces discomfort for patients and chances of infections. Given the growing geriatric population globally that is more averse to invasive treatments, the demand for painless and accurate diagnostic procedures like fusion biopsy is expected to grow steadily. Manufacturers have an opportunity to promote the enhanced patient experience, diagnostic accuracy, and quality of life benefits of fusion biopsy over traditional biopsies.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients